Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Factors secreted by the heart, referred to as “cardiokines,” have diverse actions in the maintenance of cardiac homeostasis and remodeling. Follistatin-like 1 (Fstl1) is a secreted glycoprotein expressed in the adult heart and is induced in response to injurious conditions that promote myocardial hypertrophy and heart failure. The aim of this study was to investigate the role of cardiac Fstl1 in the remodeling response to pressure overload. Cardiac myocyte-specific Fstl1-KO mice were constructed and subjected to pressure overload induced by transverse aortic constriction (TAC). Although Fstl1-KO mice displayed no detectable baseline phenotype, TAC led to enhanced cardiac hypertrophic growth and a pronounced loss in ventricular performance by 4 wk compared with control mice. Conversely, mice that acutely or chronically overexpressed Fstl1 were resistant to pressure overload-induced hypertrophy and cardiac failure. Fstl1-deficient mice displayed a reduction in TAC-induced AMP-activated protein kinase (AMPK) activation in heart, whereas Fstl1 overexpression led to increased myocardial AMPK activation under these conditions. In cultured neonatal cardiomyocytes, administration of Fstl1 promoted AMPK activation and antagonized phenylephrine-induced hypertrophy. Inhibition of AMPK attenuated the antihypertrophic effect of Fstl1 treatment. These results document that cardiac Fstl1 functions as an autocrine/paracrine regulatory factor that antagonizes myocyte hypertrophic growth and the loss of ventricular performance in response to pressure overload, possibly through a mechanism involving the activation of the AMPK signaling axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levy, D., Garrison, R. J., Savage, D. D., Kannel, W. B., & Castelli, W. P. (1990) · New England Journal of Medicine · doi:10.1056/nejm199005313222203 · Cited by 5,699
Ouchi, N., Kobayashi, H., Kihara, S., Kumada, M., Sato, K., Inoue, T., Funahashi, T., & Walsh, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310389200 · Cited by 759 · cited 2×
“These effects on myocardial capillarization are consistent with the previously described angiogenic functions of Fstl1 (31) and AMPK signaling (32, 34, 37).”
BackgroundAdiponectin-mediated modulation of hypertrophic signals in the heart
Shibata, R., Ouchi, N., Ito, M., Kihara, S., Shiojima, I., Pimentel, D. R., Kumada, M., Sato, K., Schiekofer, S., Ohashi, K., et al. (2004) · Nature Medicine · doi:10.1038/nm1137 · Cited by 671 · cited 4×
“AMPK activity is enhanced in rodent hearts after pressureoverload injury (8, 39), and gene ablation studies indicate that cardiac AMPK α2-subunit protects against the development of ventricular hypertrophy and remodeling (25).”
BackgroundMethodSelf-citationMiller, E. J., Li, J., Leng, L., McDonald, C., Atsumi, T., Bucala, R., & Young, L. H. (2008) · Nature · doi:10.1038/nature06504 · Cited by 429 · cited 2×
“Although both adiponectin and MIF have a cardioprotective function, MIF is more similar to Fstl1 in that it is induced by cardiac injury and functions as an autocrine/paracrine regulator of AMPK.”
BackgroundOuchi, N., Oshima, Y., Ohashi, K., Higuchi, A., Ikegami, C., Izumiya, Y., & Walsh, K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803440200 · Cited by 338 · cited 3×
“These effects on myocardial capillarization are consistent with the previously described angiogenic functions of Fstl1 (31) and AMPK signaling (32, 34, 37).”
BackgroundSelf-citationChan, A. Y. M., Soltys, C.-L. M., Young, M. E., Proud, C. G., & Dyck, J. R. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403528200 · Cited by 331 · cited 1×
“in vivo observations, activation of AMPK by pharmacological reagents, such as metformin or resveratrol, can reduce agoniststimulated protein synthesis and cellular growth in cultured cardiac myocytes (40, 41).”
BackgroundQuadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways
Lee, S.-J. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000789 · Cited by 316 · cited 1×
“Additionally, transgenic expression of Fstl1 from the striated muscle-specific creatine kinase M promoter had no effect on skeletal muscle mass or body weight, in marked contrast to other follistatin family members whose transgenic overexpression increased muscle mass (33).”
ResultResveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt
Chan, A. Y. M., Dolinsky, V. W., Soltys, C.-L. M., Viollet, B., Baksh, S., Light, P. E., & Dyck, J. R. B. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802869200 · Cited by 244 · cited 1×
“in vivo observations, activation of AMPK by pharmacological reagents, such as metformin or resveratrol, can reduce agoniststimulated protein synthesis and cellular growth in cultured cardiac myocytes (40, 41).”
BackgroundGenetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure
Heineke, J., Auger-Messier, M., Xu, J., Sargent, M., York, A., Welle, S., & Molkentin, J. D. (2010) · Circulation · doi:10.1161/circulationaha.109.882068 · Cited by 238
Cardiac-specific deletion of LKB1 leads to hypertrophy and dysfunction
Ikeda, Y., Sato, K., Pimentel, D. R., Sam, F., Shaw, R. J., Dyck, J. R. B., & Walsh, K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057273 · Cited by 164
Self-citation
Cited by
Sano, S., Oshima, K., Wang, Y., MacLauchlan, S., Katanasaka, Y., Sano, M., Zuriaga, M. A., Yoshiyama, M., Goukassian, D., Cooper, M. A., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.037 · Cited by 699
Self-citationPedersen, B. K. (2013) · Comprehensive physiology · doi:10.1002/cphy.c120033 · Cited by 516
Epicardial FSTL1 reconstitution regenerates the adult mammalian heart
Wei, K., Serpooshan, V., Hurtado, C., Diez-Cuñado, M., Zhao, M., Maruyama, S., Zhu, W., Fajardo, G., Noseda, M., Nakamura, K., et al. (2015) · Nature · doi:10.1038/nature15372 · Cited by 489
Self-citationAdipo-myokines: two sides of the same coin–mediators of inflammation and mediators of exercise
Raschke, S., & Eckel, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/320724 · Cited by 296
“In addition, treatment of neonatal rat ventricual cardiomyocyteswith recombinant FSTL1 induced a time- and dose-dependent increase in AMPK and ACC phosphorylation [114].”
BackgroundTherapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models
Ogura, Y., Ouchi, N., Ohashi, K., Shibata, R., Kataoka, Y., Kambara, T., Kito, T., Maruyama, S., Yuasa, D., Matsuo, K., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.115089 · Cited by 183
Self-citation
Metadata
- Authors
- Shimano, M., Ouchi, N., Nakamura, K., van Wijk, B., Ohashi, K., Asaumi, Y., Higuchi, A., Pimentel, D. R., Sam, F., Murohara, T., van den Hoff, M. J. B., & Walsh, K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-10-10
- Volume
- 108
- Issue
- 43
- Pages
- E899-906
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1988801254
- Cited by
- 133
- References
- 11
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. https://app.cochat.ai/papers/10.1073/pnas.1108559108
- The paper
- Shimano, M., Ouchi, N., Nakamura, K., van Wijk, B., Ohashi, K., Asaumi, Y., Higuchi, A., Pimentel, D. R., Sam, F., Murohara, T., van den Hoff, M. J. B., & Walsh, K. (2011). Cardiac myocyte follistatin-like 1 functions to attenuate hypertrophy following pressure overload. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1108559108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.